Journal
EYE & CONTACT LENS-SCIENCE AND CLINICAL PRACTICE
Volume 46, Issue -, Pages S64-S69Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/ICL.0000000000000666
Keywords
Keratoconjunctivitis sicca; Dry eye disease; Nanomicelles; OTX-101; Cyclosporine
Categories
Funding
- Sun Pharmaceutical Industries, Inc. (Princeton, NJ)
Ask authors/readers for more resources
Dry eye disease (DED) is among the most common reasons for visiting eye care practitioners and represents a substantial health and cost burden. Disease prevalence ranges from 5% to 33% and is increasing in the younger population. The core mechanism of DED involves a vicious cycle where hyperosmolarity leads to an inflammatory cascade resulting in ocular surface damage. No cure is available for DED, and patients require ongoing disease management. Over-the-counter medications can provide temporary symptom relief but do not tackle the inflammatory pathophysiology of DED. A number of medications with anti-inflammatory activity are available, but there is a need for development of pharmacotherapies with novel delivery methods and targets to widen the variety of treatment options. This review discusses current anti-inflammatory pharmacotherapies approved in the United States and Europe for DED and highlights novel drugs that have been recently approved or are in development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available